Business Trends– category –
-
IMS 2026 Reveals Real-World Data: eque-cel CAR-T Achieves 95.9% ORR in Relapsed/Refractory Multiple Myeloma
Targeted Oncology USA Overview The 23rd International Myeloma Society (IMS) Annual Meeting unveiled compelling real-world data for the commercial BCMA-targeted CAR-T cell therapy, equecabtagene autoleucel (eque-cel). In 281 relapsed/refr... -
GC Cell’s CD5 CAR-NK Candidate ‘GCC2005’ Achieves 62.5% ORR in Phase 1a for NK/T-Cell Lymphoma, Demonstrating Long-Term Remission and Favorable Safety
더바이오 (The Bio) South Korea Overview GC Cell announced interim Phase 1a clinical trial results for its CD5-targeting allogeneic CAR-NK therapy candidate, GCC2005, at ICBMT 2026, achieving a 62.5% objective response rate (ORR) in 8 pat... -
Boehringer Ingelheim: $1B AI RNA splicing oncology roadmap with Envisagenics
AllSci USA Overview Envisagenics has partnered with Boehringer Ingelheim in a research and option agreement valued at over $1 billion for RNA splicing-targeted oncology therapeutics. Envisagenics will leverage its AI-driven SpliceCore pl... -
Sasineprocel: Aspen Neuroscience Parkinson’s therapy data for 2026
Aspen Neuroscience Unknown Overview Aspen Neuroscience announced the publication of preclinical data for Sasineprocel, its investigational autologous iPSC-derived cell therapy for Parkinson's disease, in the prestigious journal Cell Stem... -
Fayuvi: FDA approval and specs for MPS IIIA gene therapy in 2026
CGTlive® USA Overview The FDA has granted approval to rebisufligene etisparvovec-hopf (Fayuvi), the first gene therapy for pediatric Sanfilippo Syndrome Type A (MPS IIIA). Fayuvi is a one-time intravenous AAV9 gene therapy designed to de... -
Made Scientific: 85,000 sq-ft cell therapy facility acquisition
Contract Pharma USA Overview Made Scientific has acquired an 85,000 square-foot cell therapy manufacturing facility in East Norriton, Pennsylvania, from National Resilience. The facility, designed for clinical development through commerc... -
Ryoncil: Mesoblast’s new FDA potency assay specs for GVHD drug
Mugglehead Australia Overview Mesoblast has received FDA approval for a new potency assay, the T-cell Proliferation Inhibition BioAssay (TIBA), for Ryoncil (remestemcel-L), its treatment for pediatric steroid-refractory acute Graft-versu... -
iPSC Cell Therapy: 2026 roadmap for BeiGene, BlueRock and Fate
BioInformant USA Overview As of 2026, leading companies such as BeiGene, BlueRock Therapeutics, and Fate Therapeutics are actively advancing diverse pipelines of iPSC-derived cell therapeutics. Notably, Fate Therapeutics has secured FDA ... -
Ori Biotech Secures $120M, 10-Year Partnership for Automated Cell Therapy Manufacturing; Vyriad’s In Vivo CAR-T Clears IND
RegMedNet UK Overview Ori Biotech announced a 10-year, $120 million partnership with an undisclosed biopharma firm to automate cell therapy manufacturing using its IRO platform, aiming to improve patient access. Concurrently, Vyriad secu... -
Vertex Pharmaceuticals Initiates Phase I/II for Type 1 Diabetes Cell Therapy, Expands Renal Pipeline at Morgan Stanley Conference
MarketBeat USA Overview Vertex Pharmaceuticals unveiled its ambitious growth strategy beyond cystic fibrosis at the Morgan Stanley 24th Global Healthcare Conference, emphasizing its renal pipeline and a groundbreaking cell therapy progra...
